Establishment Labs Holdings Inc. appointed Taylor Harris to its board of directors, adding a healthcare finance executive with more than 25 years of experience across medical technology, life sciences and corporate finance.
Harris currently serves on the board of Procept BioRobotics and has previously been a director at Omada Health and Endologix. Most recently, he was chief executive officer of Cutera. Before that, he was chief financial officer of MyoKardia, where he helped steer the company to Bristol Myers Squibb’s $13.1 billion acquisition.
His earlier executive roles included chief financial officer posts at Zeltiq Aesthetics, which was later acquired by Allergan, and Thoratec Corporation, which was acquired by St. Jude Medical. He also spent more than 10 years at JPMorgan Chase in healthcare equity research and investment banking.
Establishment Labs said the appointment comes as it looks to expand in the global aesthetics market. The company said its products have been delivered to plastic and reconstructive surgeons in more than 100 countries, with 5 million Motiva devices delivered since 2010. Following these announcements, the company's shares moved -0.8%, and are now trading at a price of $87.67. Check out the company's full 8-K submission here.
